Hawaii Biotechnology Group

Hawaii Biotech is a clinical-stage biotechnology company headquartered in Honolulu, Hawaii, specializing in the development of recombinant subunit vaccines for infectious diseases. The company's core technology involves the expression of truncated viral envelope proteins in Drosophila S2 cells, a platform designed to produce antigens that mimic the native viral structure. Hawaii Biotech has successfully advanced vaccine candidates for West Nile virus and Dengue fever into Phase 1 clinical trials. Beyond its lead programs, the company maintains a research pipeline targeting Ebola, Zika, and Tick-borne encephalitis. Its business model relies heavily on federal research grants and strategic collaborations to fund the development of countermeasures against global health threats.